119260-63-8

Upstream product

• 10062-40-5 17β-Dimethylamino-5-androsten-3β-ol 
• 119260-61-6 6-Hydroxymethyl-17β-dimethylamino-3-pyrrolidino-3,5-androstadiene 
• 119260-55-8 17β-Dimethylamino-3-pyrrolidino-3,5-androstadien 
• 119260-60-5 6ξ-Hydroxymethyl-17β-dimethylamino-4-androsten-3-one 
• 10063-16-8 17β-Dimethylamino-4-androsten-3-one 
• 84368-89-8 3β-acetoxy-androst-5-en-17-one oxime 
• 4350-66-7 17β-Aminoandrost-5-en-3β-ol 
• 119260-62-7 6-Hydroxymethyl-17β-dimethylamino-3β-pyrrolidino-5-androstene 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Steroids and Related Studies: Part 82 - Chandonium Related Azasteroidal Neuromuscular Blockers

Modelled on clinically active chandonium iodide (1) different azasteroidal neuromuscular blockers have been designed. 17β-Dimethylamino-3β-pyrrolidino-5-androstene dimethiodide (HS-854) (2), having not the 17a-aza-D-homo system but extranuclear quaternary ammonium head with nearly equivalent steric placement, and the 17β-dimethylamino-3α-pyrrolidino-5-androstene dimethiodide (HS-1046) (dimethiodide of 6) have been synthesized. 17β-Dimethylamino-3β-pyrrolidino-5α-androstane dimethiodide (HS-944) (7) is the dihydro analogue of HS-854 (2).The other modification, viz 6-hydroxymethyl-17β-dimethylamino-3β-pyrrolidino-5-androstene dimethiodide (HS-892) (13) has a sterically significant substituent at position-6 which should also alter hydrophilic-lipophilic balance.All the new bisquaternary steroids are active as neuromuscular blockers in the rat phrenic nerve diaphragm preparation.The structure-activity relationship has been discussed.